Cargando…
A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours
Anthracyclines are widely used in paediatric oncology, but their use is limited by the risk of cumulative cardiac toxicity. Encapsulating anthracyclines in liposomes may reduce cardiac toxicity and possibly increase drug availability to tumours. A phase I study in paediatric patients was designed to...
Autores principales: | Lowis, S, Lewis, I, Elsworth, A, Weston, C, Doz, F, Vassal, G, Bellott, R, Robert, J, Pein, F, Ablett, S, Pinkerton, R, Frappaz, D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360691/ https://www.ncbi.nlm.nih.gov/pubmed/16880787 http://dx.doi.org/10.1038/sj.bjc.6603288 |
Ejemplares similares
-
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer
por: O'Byrne, K J, et al.
Publicado: (2002) -
A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma
por: McTiernan, Anne, et al.
Publicado: (2006) -
Liposomal daunorubicin as treatment for Kaposi’s sarcoma
por: Petre, Christin E, et al.
Publicado: (2007) -
Xome-Blender: A novel cancer genome simulator
por: Semeraro, Roberto, et al.
Publicado: (2018) -
Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study
por: Doz, F, et al.
Publicado: (2001)